- Home
- HG vs WGS Comparison
HG vs WGS Comparison
Compare HG & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- WGS
- Stock Information
- Founded
- HG 2013
- WGS 2017
- Country
- HG Bermuda
- WGS United States
- Employees
- HG N/A
- WGS N/A
- Industry
- HG
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- HG
- WGS Technology
- Exchange
- HG Nasdaq
- WGS Nasdaq
- Market Cap
- HG 2.4B
- WGS 2.4B
- IPO Year
- HG 2023
- WGS N/A
- Fundamental
- Price
- HG $24.30
- WGS $123.95
- Analyst Decision
- HG Buy
- WGS Strong Buy
- Analyst Count
- HG 7
- WGS 7
- Target Price
- HG $25.71
- WGS $102.14
- AVG Volume (30 Days)
- HG 539.9K
- WGS 607.5K
- Earning Date
- HG 11-05-2025
- WGS 10-28-2025
- Dividend Yield
- HG N/A
- WGS N/A
- EPS Growth
- HG N/A
- WGS N/A
- EPS
- HG 3.61
- WGS 0.05
- Revenue
- HG $2,599,247,000.00
- WGS $362,321,000.00
- Revenue This Year
- HG $18.17
- WGS $35.84
- Revenue Next Year
- HG $8.74
- WGS $18.46
- P/E Ratio
- HG $6.77
- WGS $2,564.84
- Revenue Growth
- HG 21.31
- WGS 48.70
- 52 Week Low
- HG $16.80
- WGS $34.95
- 52 Week High
- HG $24.67
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- HG 58.95
- WGS 55.07
- Support Level
- HG $23.29
- WGS $120.55
- Resistance Level
- HG $24.67
- WGS $129.25
- Average True Range (ATR)
- HG 0.54
- WGS 5.54
- MACD
- HG -0.07
- WGS -1.82
- Stochastic Oscillator
- HG 73.94
- WGS 22.01
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.